The Hemoglobin Subunit Beta pipeline drugs market research report outlays comprehensive information on the Hemoglobin Subunit Beta targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Hemoglobin Subunit Beta pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Hematological Disorders, Oncology, and Metabolic Disorders which include the indications Sickle Cell Disease, Beta Thalassaemia, Blood Cancer, and Fabry Disease. It also reviews key players involved in Hemoglobin Subunit Beta targeted therapeutics development with respective active and dormant or discontinued products.
The Hemoglobin Subunit Beta pipeline targets constitutes close to 20 molecules. Out of which, approximately 15 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase I, Phase 0, Preclinical, and Discovery stages are 1, 1, 2, 7, and 4 respectively. Similarly, the universities portfolio in Phase II, and Preclinical comprises 2, and 3 molecule.
Hemoglobin Subunit Beta overview
Hemoglobin subunit beta (HBB) is a critical protein component of hemoglobin, the oxygen-carrying protein found in red blood cells. Encoded by the HBB gene, β-globin plays a pivotal role in transporting oxygen throughout the body. In adults, hemoglobin A (HbA), the predominant form of hemoglobin, consists of four subunits: two α-globin chains and two β-globin chains. Each β-globin chain contains an iron-binding heme group, enabling the reversible binding of oxygen molecules.
For a complete picture of Hemoglobin Subunit Beta’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
